Symposium Co-Sponsored by Syrian Endocrine Society

       Endocrinologists from Syria, Yemen, Algeria, and Morocco
                            to Participate

WORCESTER, Mass., July 17, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, will sponsor a symposium in Damascus, Syria with the Syrian Endocrine Society, on July 18, 2008. The symposium is being held to provide education and training for Middle Eastern endocrinologists on the treatment of diabetes mellitus using Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, as well as the Company's proprietary RapidMist(tm) drug delivery device. The symposium will be held at the Sheraton Sednaya Resort, hosted by the Generex MENA office. More than fifty endocrinologists from Syria, Yemen, Algeria, and Morocco are expected to participate.

The education and training sessions will be conducted by the following endocrinologists and diabetes clinical researchers: Dr. Sami Azar of the American University of Beirut; Dr. Bassam Abdul Maseh, Chairman of the Syrian Endocrine Society; Dr. Nabil Esseh of the Syrian Endocrine Society; and Dr. Nicola Napoli of University Campus Bio-Medico in Rome, Italy. The session topics will be as follows:

 * Evidence of Diabetes Treatment with Generex Oral-lyn with Dr. Azar

 * Glycemic Control & Cardiovascular Complications of Diabetes with
   Dr. Maseh

 * The New Gestational Diabetes with Dr. Esseh

 * Patient Use of Generex Oral-lyn and Patient Instruction Video with
   Dr. Napoli

Generex Oral-lyn is a non-injectable buccal insulin that is delivered into the mouth via the RapidMist device. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn does not reach the lungs. Generex Oral-lyn is designed to offer a safe, simple, fast, flexible, familiar, convenient, and pain-free alternative to prandial insulin injections.

``We are looking forward to this initial education and training session for Generex Oral-lyn in the Middle East,'' said Leo Ohanian, general manager of the Generex MENA office. ``This symposium will provide an outstanding opportunity to provide exposure for Generex Oral-lyn to top local endocrinologists as the regulatory path has commenced for a number of the countries in the region.''

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in Phase III clinical trials at several sites around the world. For more information, visit the Generex website at http://www.generex.com.

The Generex Biotechnology Corp. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as ``expects,'' ``plans,'' ``intends,'' ``believes,'' ``will,'' ``estimates,'' ``forecasts,'' ``projects,'' or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any ``phase'' of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.